These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 37280381)
41. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm? Giglio RV; Muzurović EM; Patti AM; Toth PP; Agarwal MA; Almahmeed W; Klisic A; Ciaccio M; Rizzo M J Cardiovasc Pharmacol Ther; 2023; 28():10742484231186855. PubMed ID: 37448204 [No Abstract] [Full Text] [Related]
42. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment]. Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575 [TBL] [Abstract][Full Text] [Related]
43. PCSK9 targets important for lipid metabolism. Schulz R; Schlüter KD Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216 [TBL] [Abstract][Full Text] [Related]
44. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Duprez DA; Handelsman Y; Koren M Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551 [TBL] [Abstract][Full Text] [Related]
45. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075 [TBL] [Abstract][Full Text] [Related]
47. Updates in the management of pediatric dyslipidemia. Choudhari P; Patni N Curr Opin Lipidol; 2023 Aug; 34(4):156-161. PubMed ID: 36942877 [TBL] [Abstract][Full Text] [Related]
48. Recent advances in the management and implementation of care for familial hypercholesterolaemia. Lan NSR; Bajaj A; Watts GF; Cuchel M Pharmacol Res; 2023 Aug; 194():106857. PubMed ID: 37460004 [TBL] [Abstract][Full Text] [Related]
49. Antisense oligonucleotides for the treatment of dyslipidemia. Gouni-Berthold I; Berthold HK Curr Pharm Des; 2011; 17(9):950-60. PubMed ID: 21418033 [TBL] [Abstract][Full Text] [Related]
50. Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3). Ginsberg HN; Goldberg IJ Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):388-398. PubMed ID: 36579649 [TBL] [Abstract][Full Text] [Related]
51. Alirocumab as add-on therapy to statins: current evidence and clinical potential. Auer J; Berent R Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380 [TBL] [Abstract][Full Text] [Related]
60. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E; Salvetti M High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]